Pharvaris: FDA Lifts Hold of Deucrictibant for Prophylactic Treatment of HAE

  Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant for the prophylactic treatment of HAE attacks following review of data from a 26-week rodent toxicology study.

https://www.biospace.com/article/releases/pharvaris-announces-fda-lifting-of-the-clinical-hold-of-deucrictibant-for-the-prophylactic-treatment-of-hae-attacks/